Navigation Links
Fuisz Pharma Announces Novel Anti Abuse System for Opiates
Date:1/27/2010

MIAMI and LJUBLJANA, Slovenia, Jan. 27 /PRNewswire/ -- Fuisz Pharma today announced the development of a novel anti-abuse system intended for use with abuse prone drugs. This system seeks to address the misuse of addictive drugs with a particular emphasis on opiates and is applicable to all dosage forms.

Fuisz Pharma President, Joseph Matus Fuisz commented: "The desirability of an effective anti abuse system is well understood. The United States Government has estimated that thirty six million Americans will abuse a medication at some point in their lifetime. Abuse is particularly prevalent in the pain area. Notwithstanding this need, the industry has found it challenging to implement abuse resistant dosage forms despite Herculean formulation efforts. This is due primarily to the fundamental tension between the bioavailability of a drug in the body and the prevention of extraction from the dosage form and other types of misuse by a highly motivated and sophisticated population of abusers."

Mr. Fuisz continued: "The Fuisz system for preventing abuse combines, as the best inventions do, novelty with simplicity. We are confident that our anti-abuse system will be welcomed by our pharmaceutical partners as well as by those concerned with drug misuse issues and the public and private health practitioner."

Noted pharmaceutical inventor Richard C. Fuisz, M.D. (http://en.wikipedia.org/wiki/Richard_Carl_Fuisz) was one of the inventors of the methodology.

Fuisz Pharma is a private pharmaceutical company originated by the Fuiszes. The Fuiszes have made substantial contributions in drug delivery (orally dissolving tablets and novel particle coating systems at Fuisz Technologies; inventing and developing thin film drug delivery technologies at Kosmos Pharma and MonoSol Rx, etc.) and have extensive experience working with big and specialty pharma. Fuisz Pharma has offices in Miami and Los Angeles as well as a presence in the EU through Ljubljana, Slovenia.

SOURCE Fuisz Pharma


'/>"/>
SOURCE Fuisz Pharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product
2. Pharma CI Conference Amy Yueh Pays $52,000 to Apaporis LLC to Satisfy Judgment Against Her In Superior Court Of New Jersey Case
3. Steven Leventer Joins PharmaNet Development Group as Vice President, Clinical Research Neuroscience
4. Intercept Pharmaceuticals Raises $25 Million Series B Financing
5. Pharma Billionaire Stewart Rahr Provides Substantial Donation to Haiti Charities
6. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
7. Amylin Pharmaceuticals to Webcast Year-End Financial Results
8. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
9. New Life Agency, Inc. Joins Forces With The Diamond Institute and Walgreens Specialty Pharmacy to Introduce the Nations First In Vitro Fertilization Insurance Program
10. New White Paper Examines Advanced Mycoplasma Tests - How Real-Time PCR Analysis Helps Save Time and Money for Biopharmaceutical Manufacturers
11. Sagent Pharmaceuticals Launches Pamidronate Disodium Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... 20, 2017   ZappRx, Inc ., a digital health ... process, today announced it closed $25 million in Series B ... firm based in Seattle that is ... . The Series B round included participation from SR ... and GV (formerly Google Ventures). As part of ...
(Date:4/20/2017)... -- Eyevensys, a private biotechnology company developing ... technology that enables the safe, local, sustained production of ... range of ophthalmic diseases, announces it has received approval ... (MHRA) to advance its technology into clinical development. ... The EyeCET platform ...
Breaking Medicine Technology:
(Date:4/29/2017)... ... April 29, 2017 , ... TransDark is a set of dynamic transitions ... the next without having to set a single keyframe in Final Cut Pro ... video production. , TransDark features dynamic transitions that momentarily splits the RGB layers of ...
(Date:4/28/2017)... ... April 28, 2017 , ... An April 24th article on Yahoo! Beauty discusses ... with the help of a weight loss surgery. The woman, declaring “I will not hate ... been left following her dramatic weight loss. Dr. Feiz & Associates notes that, while it ...
(Date:4/28/2017)... ... 2017 , ... Beginning in 2017, Ridgecrest Herbals will be phasing out the ... ClearLungs Extra Strength formula. To ensure that the effectiveness of Clear Lungs Extra Strength ... , Removal of the homeopathic element , Adding their ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio ... These lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most ... disconnect ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving ...
(Date:4/28/2017)... ... April 28, 2017 , ... From April 30 to May ... Medicine will host industry leaders for the annual spring Convention & Expo, called ... industry adapt to the issues currently affecting urgent care and on-demand healthcare. , ...
Breaking Medicine News(10 mins):